How to buy Scisparc stock (Scisparc)

Scisparc is a biotechnology business based in the US. Scisparc shares (SPRC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.43 – an increase of 101.13% over the previous week. Scisparc employs 3 staff and has a trailing 12-month revenue of around $1.7 million.

Our top picks for where to buy Scisparc stock

Buy Scisparc stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Scisparc stock price (NASDAQ: SPRC)

Use our graph to track the performance of SPRC stocks over time.

Scisparc shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$0.43
52-week range	$0.20 - $6.72
50-day moving average more info button	$0.24
200-day moving average more info button	$0.74
Wall St. target price	N/A
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-5.28

Is it a good time to buy Scisparc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Scisparc price performance over time

Historical closes compared with the close of $0.5 from 2024-12-26

1 week (2024-12-20)	134.41%
1 month (2024-11-27)	126.96%
3 months (2024-09-27)	100.00%
6 months (2024-06-28)	-37.50%

1 year (2023-12-28)	-89.80%
2 years (2022-12-28)	-97.37%
3 years (2021-12-28)	174.2
5 years (2019-12-24)	N/A

Scisparc financials

Revenue TTM	$1.7 million
Gross profit TTM	$1 million
Return on assets TTM	-38.85%
Return on equity TTM	-85.91%
Profit margin	0%
Book value	$1.93
Market Capitalization more info button	$2.3 million

TTM: trailing 12 months

Scisparc share dividends

We're not expecting Scisparc to pay a dividend over the next 12 months.

You may also wish to consider:

Have Scisparc's shares ever split?

Scisparc's shares were split on a 1:26 basis on 27 September 2023 . So if you had owned 26 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Scisparc shares – just the quantity. However, indirectly, the new 2500% higher share price could have impacted the market appetite for Scisparc shares which in turn could have impacted Scisparc's share price.

Scisparc share price volatility

Over the last 12 months, Scisparc's shares have ranged in value from as little as $0.197 up to $6.72. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Scisparc's is 1.037. This would suggest that Scisparc's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

To put Scisparc's beta into context you can compare it against those of similar companies.

• Corbus Pharmaceuticals Holding (CRBP.US): 2.565
• Cara Therapeutic (CARA.US): 0.681
• Amyris (AMRS.US): 1.1895

Scisparc overview

SciSparc Ltd. , a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd.

Frequently asked questions

What percentage of Scisparc is owned by insiders or institutions?
Currently 0.002% of Scisparc shares are held by insiders and 1.73% by institutions. How many people work for Scisparc?
Latest data suggests 3 work at Scisparc. When does the fiscal year end for Scisparc?
Scisparc's fiscal year ends in December. Where is Scisparc based?
Scisparc's address is: Tower A, Tel Aviv, Israel, 6971916 What is Scisparc's ISIN number?
Scisparc's international securities identification number is: IL0010951403